Hear From Industry Experts.
From world-renowned academic medical centers to specialized care programs, our technology is transforming the way healthcare is delivered.
Institutions like MD Anderson Cancer Center, Cleveland Clinic’s Glickman Urological & Kidney Institute, Samved Urology Hospital, and others rely on our solutions to drive clinical excellence, improve outcomes, and enhance patient care.
Discover what these leading organizations have to say about partnering with us.
Currently available clinical and pathological tools are limited in their ability to predict disease recurrence after initial therapy for early stage and locally advance prostate cancer. The AI-powered PATHOMIQ tool holds promise to change that and identify those at highest risk of recurrence by image-based analysis of image-based analysis of initial biopsy or prostatectomy samples. This technology is non-destructive, has fast turn-around time, identifies “hot spots” that will allow deeper proteogenomic analysis to help identify the drivers of progression, and as such is a promising approach to define more personalized outcome predictions and therapies.
Chair of the Glickman Urological & Kidney Institute
Professor of Surgery, Lerner College of Medicine, Cleveland Clinic
At present, there is no biomarker that can predict triple negative breast cancer response to standard-of-care neoadjuvant chemotherapy. A biomarker that can reliably predict response to chemotherapies at the time of the initial diagnosis would have far reaching clinical implications such as the personalization of cytotoxic and immunotherapy regimens that would optimize both safety and efficacy. We are very excited about the performance of PATHOMIQ’s AI-enabled morphometric biomarker from H&E slides that could be translated into the clinic for personalized treatment selection for each patient in the near future.
Chairman, Department of Breast Medical Oncology, MD Anderson Cancer Center
This is the first demonstration of using an AI tool on digitized H&E tissue images to predict response to NAC in patients with TNBC with high accuracy.
Professor, Department of Pathology, MD Anderson Cancer Center
With the aging of the world population, the prostate cancer incidence is on the rise. About 70% of the men diagnosed with prostate cancer will have indolent tumors, who can be kept under observation without any intervention or be cured after the first line therapy with surgery and/or ionizing radiation. Inaccuracy of the current clinical methods in identifying these men at the time of diagnosis leads to unnecessary intervention or missing some patients, who could have benefitted with early, aggressive therapies. I am excited to see the high degree of accuracy in PATHOMIQ AI-powered tool for identifying these patients from images of their primary biopsies that will immensely help better decision making for each patient. Additionally, PATHOMIQ’s image based, fast turn-over and non-destructive analysis will allow deeper genomic analysis of the cancer driving areas to refine personalized therapies at an earlier stage of the disease leading to better success rate with lesser side effects.
Urologist, Samved Urology Hospital
Currently used clinical methods of identifying prostate cancer patients whose tumor will remain indolent from those who are at a high risk of cancer progression to aggressive metastatic disease in a short time have low accuracy rate. This results in uncertainty in clinical decision making leading to unnecessary intervention for many patients, leading to considerable and needless side effects, morbidity, and expense, while missing some high-risk patients, who could have benefitted from early intervention. I am excited to co-develop with the PATHOMIQ team, the PATHOMIQ_PRAD AI model for prostate cancer treatment response prediction and identify high-risk prostate cancer patients who experience early metastasis post-surgery. This AI model has outperformed currently used markers in both Caucasian and African American patient cohorts for a much-improved outcome.
Director of Robotic Prostatectomy, Precision Urology Director, Prostate Cancer Program
PATHOMIQ AI, headquartered in Silicon Valley, USA, was founded by a multidisciplinary team of outstanding biomarker discovery researchers, data scientists, and clinicians with 100+ man-years of experience in their areas of specialty.
CEO & Co-Founder
Chief Medical Officer
Head of Pathology &
Co-Founder
